Abstract-Corticotropin-releasing factor (CRF) and CRF-related neuropeptides are involved in the regulation of stressrelated physiology and behavior. Members of the CRF family of neuropeptides bind to two known receptors, the CRF type 1 (CRF 1 ) receptor, and the CRF type 2 (CRF 2 ) receptor. Although the distribution of CRF 2 receptor mRNA expression has been extensively studied, the distribution of CRF 2 receptor protein has not been characterized. An area of the brain known to contain high levels of CRF 2 receptor mRNA expression and CRF 2 receptor binding is the dorsal raphe nucleus (DR). In the present study we investigated in detail the distribution of CRF 2 receptor immunoreactivity throughout the rostrocaudal extent of the DR. CRF 2 receptor-immunoreactive perikarya were observed throughout the DR, with the highest number and density in the mid-rostrocaudal DR. Dual immunofluorescence revealed that CRF 2 receptor immunoreactivity was frequently co-localized with tryptophan hydroxylase, a marker of serotonergic neurons. This study provides evidence that CRF 2 receptor protein is expressed in the DR, and that CRF 2 receptors are expressed in topographically organized subpopulations of cells in the DR, including serotonergic neurons. Furthermore, these data are consistent with the hypothesis that CRF 2 receptors play an important role in the regulation of stress-related physiology and behavior through actions on serotonergic and non-serotonergic neurons within the DR.
Corticotropin-releasing factor (CRF) is a 41-amino acid neuropeptide that has been linked to the regulation of stress-related physiology and behavior, including regulation of the hypothalamic-pituitary-adrenal (HPA) axis (Vale et al., 1981 (Vale et al., , 1983 . The CRF family of neuropeptides also includes urocortin (Ucn) 1, Ucn 2, and Ucn 3; the role of these CRF-related neuropeptides in the HPA axis and stress-related physiological and behavioral responses is less clear, although evidence suggests that they also play an important role in modulating these responses (Reul and Holsboer, 2002) . CRF and its family of neuropeptides are known to bind to two distinct G protein-coupled receptors, the CRF type 1 (CRF 1 ) receptor, and the CRF type 2 (CRF 2 ) receptor (Perrin et al., 1993; Lovenberg et al., 1995b) , for which they have different binding affinities. CRF preferentially binds to CRF 1 receptors, Ucn 1 binds with high affinity to both receptors, and Ucn 2 and Ucn 3 preferentially bind to CRF 2 receptors Reyes et al., 2001) . Whereas CRF 1 receptors have a widespread distribution in the CNS, including subcortical and cortical regions, CRF 2 receptor distribution is mainly limited to subcortical structures (Chalmers et al., 1995; Radulovic et al., 1998; Sanchez et al., 1999; Van Pett et al., 2000; Chen et al., 2000; Korosi et al., 2006) .
Multiple isoforms of the CRF 2 receptor are known to be expressed including the alpha, beta, and gamma (found only in humans) isoforms, a soluble isoform, and a truncated isoform (currently described only in rats). These isoforms have distinct expression patterns and binding affinities for CRF and its family of peptides (Lovenberg et al., 1995a; Kostich et al., 1998; Miyata et al., 1999 Miyata et al., , 2001 Chen et al., 2005b; Evans and Seasholtz, 2009) .
A subcortical area of the rat CNS that contains a high density of cells expressing CRF 2 receptor mRNA expression is the dorsal raphe nucleus (DR). The DR is a brainstem region that, together with the median raphe nucleus (MnR), contains the majority of serotonergic neurons with ascending projections to forebrain structures (Steinbusch et al., 1978; Steinbusch, 1981) . In situ hybridization studies have shown that the DR is one of a few brain regions that contain more CRF 2 receptor mRNA expression than CRF 1 receptor mRNA expression in rats (Van Pett et al., 2000; Day et al., 2004; Korosi et al., 2006) . Co-localization studies in rat brain have shown that CRF 2 receptor mRNA expression within the DR is localized predominantly in serotonergic neurons, although, in caudal parts of the DR, CRF 2 receptor mRNA expression is commonly found in non-serotonergic neurons, including GABA-synthesizing GABAergic neurons (Day et al., 2004) . Consistent with these findings, and consistent with expression of functional receptor protein in the DR, dense CRF 2 receptor binding has been described in the DR of several vole species (Lim et al., 2005) .
Although the distribution of CRF 2 receptor mRNA expression has been extensively studied, the distribution of CRF 2 receptor protein has not been characterized. This could be due to (1) difficulties generating CRF 2 receptorspecific antibodies, (2) antibodies used in many previous studies, such as the CRF 1/2 receptor antibody sc-1757 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), recognize both CRF 1 and CRF 2 receptors (Campbell et al., 2003; Chen et al., 2000; Hinkle et al., 2003, also see Fig. 4) , and (3) some CRF 2 receptor-specific antibodies used in previous studies (Waselus et al., 2009; Wang et al., 2007) are no longer commercially available. Recent studies using immunoelectron microscopy have demonstrated that CRF 2 receptor immunoreactivity is predominantly intracellular in DR neurons under basal unstressed conditions, and shifts toward a greater expression at the plasma membrane following stress exposure (Waselus et al., 2009 ). The shift in intracellular versus plasma membrane localization of CRF 2 receptors is associated with a shift from inhibitory to excitatory neuronal firing rate responses to CRF administration (Waselus et al., 2009) .
The hypothesis that functional CRF 2 receptors are expressed in the DR is supported by studies using immediate-early gene expression (e.g. nuclear c-Fos induction representing increased cellular responses) and electrophysiology to investigate the effects of CRF 2 receptor ligands on responses of serotonergic neurons in the DR. I.c.v. injections of the CRF 2 receptor ligand mouse Ucn 2 (mUcn 2) (Staub et al., 2005) or microinjections of mUcn 2 directly into the DR (Amat et al., 2004) increase c-Fos expression in DR serotonergic neurons and increase serotonin release in DR projection sites, while pretreatment with the CRF 2 receptor antagonist [DPhe11, His12]sauvagine(11-40) (antisauvagine-30; ASV-30) blocks these effects (Amat et al., 2004; Staub et al., 2006) . Likewise, electrophysiological studies in anesthetized rats have shown that injections of mUcn 2 directly into the DR can increase the firing rates of serotonergic neurons and these effects can be prevented by pretreatment with ASV-30 (Pernar et al., 2004) . Together, these studies are consistent with the finding that activation of CRF 2 receptors in the DR increases extracellular serotonin concentrations within the basolateral amygdaloid nucleus (Amat et al., 2004) and nucleus accumbens (Lukkes et al., 2008) , forebrain targets of serotonergic neurons arising from the DR (Abrams et al., 2005; Van Bockstaele et al., 1993) .
Understanding the distribution of CRF 2 receptors within the DR is important because there is increasing evidence that the DR may include anatomically and functionally distinct subpopulations of serotonergic neurons (Imai et al., 1986; Abrams et al., 2004; Lowry et al., 2005 Lowry et al., , 2008 Lowry and Hale, 2010) . Indeed, serotonergic neurons can be divided into several different types, some of which are restricted to specific regions of the DR, based on their physiological properties and behavioral correlates (Rasmussen et al., 1984; Fornal et al., 1996; Jacobs and Fornal, 1999; Sakai and Crochet, 2001; Kocsis et al., 2006) .
Several studies suggest that interactions between CRF or CRF-related ligands and serotonergic systems may play an important role in the regulation of anxiety-related behaviors in rats (Maier and Watkins, 2005; Lowry et al., 2005) and anxiety and affective disorders in humans (Arborelius et al., 1999; Austin et al., 2003) . These data, together with (1) the potential for mismatch between CRF 2 receptor mRNA and protein expression in neurons within the DR, (2) the potential for expression of multiple isoforms of the CRF 2 receptor, and (3) the evidence for anatomical and functional heterogeneity within the DR, led us to characterize the detailed topographical organization of CRF 2 receptor protein expression within this brainstem region and the extent of its co-localization with cytoplasmic tryptophan hydroxylase (TrpOH), a marker of serotonergic neurons. These studies used an antibody directed against the N-terminus of the CRF 2 receptor, including an epitope that is highly conserved among CRF 2␣ and CRF 2␤ receptor isoforms, and therefore is likely to detect all known CRF 2 receptor isoforms in rat brain, including truncated isoforms of the receptor.
EXPERIMENTAL PROCEDURES DR immunohistochemistry
Animals. Adult male Sprague Dawley rats (nϭ8; 250 -300 g; Harlan Laboratories, Indianapolis, IN, USA) were used. The rats were group housed, two per cage, in wire cages (17ϫ35ϫ45 cm 3 ; Alternative Design, Siloam Springs, AR, USA) and were maintained with free access to food and water under a 12 h light/dark cycle with lights on at 0700 h in a room with standard temperature (21°C) and humidity (22%). Rats were acclimated for at least 1 week before experimental manipulation. All procedures were approved by the University of Colorado at Boulder Institutional Animal Care and Use Committee. In addition, all studies were consistent with the NIH Guide for the Care and Use of Laboratory Animals (N.I.H. Publication No. 85-23). All possible efforts were made to minimize the number of animals used and their suffering.
Mice lacking functional CRF 1 receptors (nϭ3) and wild type littermates (nϭ3) (Smith et al., 1998) were maintained with free access to food and water under a 12 h light/dark cycle. All experimental protocols were approved by The Weizmann Institute of Science Institutional Animal Care and Use Committee. Mice lacking functional CRF 2 receptors were not used as methods used to develop the existing CRF 2 mutants did not delete the 5'region of the gene encoding the N-terminus of the CRF 2 receptor, the region that is targeted by the anti-CRF 2 receptor antibody used in this study.
Tissue processing. Rats or mice were anesthetized with 0.5 ml sodium pentobarbital (200 mg/ml; Vortech Pharmaceuticals, Dearborn, MI, USA). Animals were transcardially perfused with 150 ml of 0.1 M phosphate buffered saline (PBS; pH 7.4) at room temperature (RT), followed by 200 ml of cold (4°C) 4% paraformaldehyde (prepared using 40 g paraformaldehyde, 404 ml 0.2 M Na 2 HPO 4 , 96 ml 0.2 M NaH 2 PO 4 , and 500 ml dH 2 O, brought to pH 7.4 with sodium hydroxide pellets). Brains were removed from the cranium, postfixed for 1 h in the same fixative at 4°C, then immersed in 0.1 M PBS with 25% sucrose and stored for 2 days at 4°C. Following cryopreservation with sucrose, brains were then blocked in a coronal plane using a rat (RBM-4000C, ASI Instruments, Warren, MI, USA) or mouse (RBM-2000C, ASI Instruments) brain matrix; brains were cut in the coronal plane at the caudal border of the mammillary bodies (approximately Ϫ5.30 mm bregma in rat brains or Ϫ2.80 mm bregma in mouse brains) and rapidly frozen in liquid isopentane chilled on dry ice. The brains were stored at Ϫ80°C until sectioning. Brain sections (30 m) were made using a cryostat and stored as six alternate sets of sections at Ϫ20°C in cryoprotectant (prepared using 270 ml ethylene glycol, 160 ml glycerol, 202 ml 0.2 M Na 2 HPO 4 · 7H 2 O, 48 ml 0.2 M NaH 2 PO 4 · H 2 O, and 320 ml dH 2 O) until immunostaining was performed.
Immunohistochemistry. For immunostaining, every sixth section of the midbrain containing the DR (from approximately Ϫ5.8 to Ϫ10.3 mm bregma in rat brains; approximately Ϫ3.5 to Ϫ5.7 mm bregma in mouse brains) was removed from the cryoprotectant and washed in 0.01 M PBS for 15 min. The tissue was then placed in 0.01 M PBS containing 1% H 2 O 2 for 15 min and then sections were washed twice in 0.01 M PBS for 15 min each. Sections were then preincubated in blocking buffer (0.01 M PBS, pH 7.4, containing 1% normal rabbit serum, Cat. No. 011-000-120, Jackson ImmunoResearch, West Grove, PA, USA) at RT for 2 h to reduce non-specific staining. Sections were then incubated in goat anti-CRF 2 receptor-selective polyclonal antibody (1:300; Cat. No. sc-1826; Santa Cruz Biotechnology, Santa Cruz, CA, USA) in 0.01 M PBS containing 0.04% normal rabbit serum and 0.2% Triton X-100 for 20 h at 4°C with gentle agitation (Lukkes et al., 2009) . Sections were washed in 0.01 M PBS containing 0.04% normal rabbit serum two times for 15 min, and incubated for 2 h at RT in biotin-conjugated donkey anti-goat secondary antibody (1: 200; , Jackson ImmunoResearch) in 0.01 M PBS containing 0.04% normal rabbit serum and 0.03% Triton X-100 to visualize CRF 2 receptor-like immunoreactivity. After incubation with secondary antibody, sections were washed in 0.01 M PBS containing 0.04% normal rabbit serum two times for 15 min, and then placed in an avidin-biotin-peroxidase complex (ABC) reagent (Cat. No. PK-6106; Vector Laboratories, Burlingame, CA, USA) at 1:200 in 0.01 M PBS for 90 min. The tissue was then rinsed in 0.01 M PBS two times for 15 min each. The tissue was then placed in a peroxidase-based substrate reaction (Vector SG chromogen kit; Cat. No. SK-4700; Vector Laboratories) for 6 min. The reaction was stopped by rinsing the tissue in 0.01 M PBS for 15 min. After this the tissue was briefly rinsed in 0.1 M sodium phosphate buffer (PB) and mounted onto clean glass microscope slides. Once mounted the sections were dehydrated, cleared with xylene, and mounted with cover slips.
Immunocytochemistry. Human embryonic kidney (HEK-293) cells that stably express the mouse CRF 2␣ receptor and enhanced green fluorescent protein (EGFP) and wild type (WT) HEK-293 cells were used to determine the specificity of the anti-CRF 2 receptor antibody (Chen et al., 2005a 
Western blot, microdissected brain regions
Adult male Sprague Dawley rats (nϭ2; 250 -300 g; Harlan Laboratories) were maintained as described above for immunohistochemical procedures and used for western blots. Western blots were performed to determine the relative molecular weight of the protein(s) recognized by the CRF 2 receptor antibody used, and to determine the relative amounts of CRF 2 receptor protein in different brain regions. Rats were decapitated, brains were then removed, frozen and stored at Ϫ80°C, and then sectioned frozen (300 m) using a cryostat (Leica CM 1900; North Central Instruments, Plymouth, MN, USA) at Ϫ12°C. The motor cortex (M1), entorhinal cortex (En), lateral septum (LS), ventromedial hypothalamus (VMH), median raphe nucleus (MnR), and DR were dissected at Ϫ10°C using the Palkovits punch technique (Palkovits and Brownstein, 1988 ) and a 22 gauge cannula (Cat. No. 18036-22; 0.41 mm internal diameter; Fine Science Tools, Foster City, CA, USA). Tissue was then homogenized in 60 l of HEPES buffer (Cat. No. H3375; Sigma-Aldrich, St. Louis, MO, USA) containing 2.4 l protease inhibitor stock "complete" (1:25 dilution; Roche Diagnostics Ltd, Indianapolis, IN, USA). Total protein concentrations were determined within 5 l sample duplicates using a Pierce protein assay (Cat. No. 1856210; Thermoscientific, Rockford, IL, USA) and a microplate reader (MultiSkan EX 355; Thermo Electron Corporation, Waltham, MA, USA). Samples (30 g total protein) were processed for western blotting, and CRF 2 receptor and actin levels were detected using methods described previously (Lukkes et al., 2009) . Briefly, protein was mixed in 1ϫ sodium dodecyl sulfate (SDS)/␤-mercaptoethanol loading buffer, vortexed and boiled for 3 min prior to separation by 8% SDSpolyacrylamide gel electrophoresis. Following electrophoresis (Mini-PROTEAN 3 cell, Bio-Rad Laboratories, Hercules, CA, USA), proteins were transferred to a polyvinylidene fluoride (PVDF) membrane (Immuno-Blot; 0.2 m, Bio-Rad Laboratories). The membranes were blocked with 5% non-fat dry milk in Trisbuffered saline containing 0.1% Tween-20 (TBS-T) for 20 min at RT and incubated with goat anti-CRF 2 receptor polyclonal antibody (1:100; Cat. No. sc-1826; Santa Cruz Biotechnology) in 5% non-fat dry milk in TBS-T overnight at 4°C. The membranes were rinsed three times for 10 min each time at RT in TBS-T. After the rinsing procedure, the membranes were incubated for 2 h at RT in affinity-purified rabbit anti-goat IgG (whole molecule)-peroxidase conjugated secondary antibody (1:30,000; Cat. No. A5420; Sigma-Aldrich) in 5% non-fat dry milk in TBS-T. Control for protein loading was achieved by using mouse anti-actin primary antibody (1:2000; Cat. No. MAB1501R; Chemicon International, Billerica, MA, USA) and goat anti-mouse IgG (Fab specific)-peroxidase conjugated secondary antibody (1:5000; Cat. No. A3682, SigmaAldrich) in 5% non-fat dry milk in TBS-T. Proteins were detected using a ChemiDoc-IT imaging system with cooled CCD camera (UVP Bioimaging Systems, Upland, CA, USA).
Antibodies
The goat anti-CRF 2 receptor antibody used (N-20, Cat. No. sc-1826, Santa Cruz Biotechnology) is an affinity-purified polyclonal antibody raised against a peptide corresponding to amino acid sequence 47-66 mapping at the N-terminus of the CRF 2␤ receptor of mouse origin (RTTIGNFSGPYTYCNTTLDQ) (Fig. 1 ). There is no similarity with the amino acid sequence of the CRF 1 receptor (only four of 20 amino acids are conserved; Fig. 1 ). The sequence used to generate the antibody is unique based on a search of the basic local alignment search tool (BLAST) database; this does not preclude the possibility that there are peptides that have not been characterized that have similar sequences.
The goat anti-CRF 1/2 receptor antibody used (C-20, Cat. No. sc-1757, Santa Cruz Biotechnology) is a polyclonal antibody raised against a peptide corresponding to amino acid sequence 396 -415 mapping at the C-terminus of the CRF 1 receptor of human origin (SIPTSPTRVSFHSIKQSTAV). There is a three-amino acid difference between the rat CRF 1 and rat CRF 2 receptor at the region that corresponds to this sequence. Western blot analysis indicates that this antibody recognizes a band corresponding to the predicted molecular weight of the CRF 1 receptor in mice 77-80 kDa (Radulovic et al., 1998; Chen et al., 2000) .
Analysis of the distribution of CRF 2 receptor immunoreactivity
For analysis, the DR was divided into rostral (Ϫ6.92 to Ϫ7.64 mm bregma), mid-rostrocaudal (Ϫ7.73 to Ϫ8.45 mm bregma), and caudal (Ϫ8.54 to Ϫ9.26 mm bregma) regions (Abrams et al., 2004) . Analysis of CRF 2 receptor immunostaining in the DR was performed at 12 anatomical levels at 180 m intervals (rostral DR; mid-rostrocaudal DR; and caudal DR; one section/ level/rat). At each level the DR was further divided into different regions. These regions were the dorsal part of the DR (DRD), the ventral part of the DR (DRV), the ventrolateral part of the DR and ventrolateral periaqueductal gray (DRVL/VLPAG), the caudal part of the DR (DRC; subdivided into dorsal (dDRC) and ventral (vDRC) parts at Ϫ9.08 mm bregma), and the interfascicular part of the DR (DRI). The rostrocaudal levels and subdivisions were defined based on a standard rat brain stereotaxic atlas (Paxinos and Watson, 1998) .
CRF 2 receptor/TrpOH double immunofluorescence
Adult male Sprague Dawley rats (nϭ6; 250 -300 g; Harlan Laboratories) were maintained as described above for immunohistochemical procedures and used for CRF 2 receptor/TrpOH double immunofluorescence.
Immunofluorescence was used to identify CRF 2 receptorexpressing and TrpOH-expressing cells because this method provides the cellular resolution required to determine co-localization of CRF 2 and TrpOH immunoreactivity. Perfusion and postfixation methods were as described above for CRF 2 receptor immunohistochemistry.
For immunofluorescence, every sixth section of the midbrain containing the DR (from approximately Ϫ7.64 to Ϫ8.54 mm bregma) was removed from the cryoprotectant and washed in 0.05 M PBS twice, for 15 min each time. Sections were then incubated in 0.05 M PBS containing 0.3% Triton X-100 (PBST) and 0.01% sodium azide for 60 min at RT and then placed in Amino acid sequences of the N-termini, up to the first predicted transmembrane domain, of mouse and rat CRF 2␣ and CRF 2␤ isoforms of the CRF 2 receptor, as well as a soluble form of the mouse and rat CRF 2␣ receptor, a truncated form of the rat CRF 2␣ receptor, and the rat CRF 1 receptor. Black line indicates the amino acid sequence corresponding to the 20-amino acid peptide from the mouse CRF 2␤ receptor isoform that was used as the antigen for development of the polyclonal CRF 2␤ receptor antibody (sc-1826) used in this study. Amino acid sequences were obtained from the following sources: mCRF 2␤ (Perrin et al., 1995) (NCBI Protein database accession no.: Q60748), rCRF 2␤ (NCBI Protein database accession no.: EDL88098), mCRF 2␣ (Chen et al., 2005a ) (NCBI Protein database accession no.: AAS07021), mCRF 2␣sol (Chen et al., 2005b; Evans and Seasholtz, 2009 ), (NCBI Protein database accession no.: AAU94301), rCRF 2␣ -tr receptor (Miyata et al., 1999) , rCRF 2␣ (Lovenberg et al., 1995b ) (NCBI Protein database accession no.: NP_073205), rat CRF 2␣sol (Evans and Seasholtz, 2009 ), rCRF1 receptor (Perrin et al., 1993) 011-000-120, Jackson ImmunoResearch) and 0.2% Triton X-100 for 20 h at 4°C with gentle agitation (Lukkes et al., 2009 ). Sections were then washed in 0.01 M PBS containing 0.04% normal rabbit serum two times for 15 min each time, and incubated for 2 h at RT in FITC-conjugated donkey anti-goat IgG secondary antibody (1:200; Cat. No. 705-095-147, peak emission 520 nm, green fluorescence; Jackson ImmunoResearch) in 0.01 M PBS containing 0.04% normal rabbit serum to visualize CRF 2 receptor immunofluorescence. After incubation in secondary antibody, sections were washed in 0.01 M PBS containing 0.04% normal rabbit serum two times for 15 min each time and mounted onto glass slides, then cover-slipped with 4',6-diamidino-2-phenylindole DAPI Vectashield (Cat. No. H-1200, Vector Laboratories), which fluorescently stains cell nuclei.
Quantification of CRF 2 receptor/TrpOH double immunofluorescence
For each subject (nϭ6; Sprague Dawley rats; Harlan Laboratories), 100ϫ and 200ϫ magnification photomicrographs were generated for regions of interest using a Nikon 90i microscope and a Roper Scientific CoolSNAP ES digital camera linked to a computer with NIS Elements imaging software (A.G. Heinze Inc., Lake Forest, CA, USA). The 100ϫ photomicrographs were used to identify and document the rostrocaudal level of the sample; 200ϫ photomicrographs were used for quantification with each subdivision. For each photomicrograph, the region of interest we placed in the center of the field of view using the 20ϫ objective lens and then photographs were taken using FITC, Cy5, and DAPI filters. Analysis of fluorescence in the DR and pontine raphe nucleus (PnR) was performed at six anatomical levels (Ϫ7.46, Ϫ7.64, Ϫ8.00, Ϫ8.18, Ϫ8.54, and Ϫ9.16 mm bregma; one section/level/rat; Fig. 2) , within the DRD, DRV, DRVL/VLPAG, DRI, DRC and PnR. The anatomical levels and subdivisions were defined based on a rat brain atlas (Abrams et al., 2004; Paxinos and Watson, 1998) . Cell counts collected from photomicrographs were probably not biased by differences in cell number or density, as photomicrographs were obtained at a plane of focus in the middle of the tissue sections, which were 30 m thick. Separate layers for CRF 2 receptor-immunoreactive (ir) and TrpOH-ir photomicrographs were created using Adobe Photoshope CS (Adobe Systems Incorporated, San Jose, CA, USA). The numbers of CRF 2 receptor-ir and TrpOH-ir neurons were quantified by placing dots over each CRF 2 receptor-ir and TrpOH-ir profile in additional cell counting layers. The cell counting layers were superimposed and the numbers of single-labeled CRF 2 receptor-ir cells, single-labeled TrpOH-ir neurons, and double-labeled neurons were counted. Double-labeled (CRF 2 receptor-ir/TrpOH-ir) neurons were confirmed with the slides themselves using 400ϫ magnification.
Image capture
Brightfield photomicrographs were taken using a Nikon 90i microscope and a Nikon DS-Fi1 digital camera linked to a computer with NIS Elements 3.00 imaging software (A.G. Heinze Inc., Lake Forest, CA, USA). Low magnification images of immunofluorescence in cell culture studies were generated using a Leica DMRB fluorescence microscope, a Leica DC500 camera, and image capture software (Leica Microsystems, Heidelberg, Germany). Confocal images of immunofluorescence in cell culture studies were generated using a Leica TCS SP2 AOBS laser scanning confocal microscope using FITC, Cy5, and DAPI filter cubes and Leica Confocal Software (v. 2.00, Leica Microsystems), presented as 8-m-thick z-stack projections. Contrast and brightness of the photographs were adjusted using Adobe Photoshop CS (Adobe Systems Incorporated, San Jose, CA, USA). Photographic plates were prepared in CorelDraw for Windows 12.0 (Viglen Ltd., Wembley, UK). 
RESULTS

Immunocytochemistry
In order to determine the specificity of the anti-CRF 2 receptor antibody used in these studies, we conducted immunocytochemical staining of wild type HEK-293 cells that are known to lack CRF 2 receptor expression (Dautzenberg et al., 2000) , and HEK-293 cells stably expressing the mouse CRF 2␣ receptor and EGFP. The anti-CRF 2 receptor antibody did not immunostain wild type HEK-293 cells (Fig.  3B ) but did immunostain HEK-293 cells stably expressing the mouse CRF 2␣ (mCRF 2␣ ) receptor (Fig. 3D) and EGFP ( Fig. 3C ; for additional controls, see Fig. 4 ). High magnification confocal images revealed that the CRF 2 receptor immunostaining was restricted to the plasma membrane and cytoplasmic compartments of the cell, while EGFP was expressed throughout the cell including the nuclear compartment ( Fig. 3E-G) .
As opposed to CRF 2 receptors, wild type HEK-293 cells are known to express CRF 1 receptors (Dautzenberg et al., 2000) . The anti-CRF 1/2 receptor antibody immunostained both the wild type HEK-293 cells and the HEK-293 cells that stably express the mCRF 2␣ receptor and EGFP (Fig. 4B, D) . The intensity of staining in the HEK-293 cells stably expressing the mCRF 2␣ receptor was greater than in the wild type HEK-293 cells, suggesting that this antibody detected both endogenous CRF 1 and, in cells stably expressing the mCRF 2␣ receptor, CRF 2 receptors (Fig. 4) . (Fig. 5E , G) and CRF 1 receptor KO mice (Fig. 5F, H) , indicating that the immunostaining was not due to cross-reactivity with CRF 1 receptors.
Western blot
The anti-CRF 2 receptor antibody recognized a band between 37 and 50 kDa (the predicted molecular weight of the full-length CRF 2␣ receptor is about 40 -45 kDa) in western blot analysis using homogenized microdissected brain regions (Fig. 6 ). All brain regions examined are known to contain CRF 2 receptor mRNA expression (Van Pett et al., 2000) , and the density of the bands in different brain regions corresponded with the density of CRF 2 receptor mRNA expression in the brain (Van Pett et al., 2000) . For example, band density was highest in the LS, whereas it was lowest in cortical regions such as the En and M1 (Fig. 6 ). There were no differences in the actin levels in different brain regions (Fig. 6 ). There was no band at the predicted molecular weight for the CRF 1 receptor (76 -80 kDa; (Radulovic et al., 1998) ) in any region examined (Fig. 6) .
CRF 2 receptor immunostaining in the rostral DR
Rostral regions of the rat DR (Ϫ6.92 mm to Ϫ7.64 mm bregma) contained a low (in the most rostral sections of the rostral DR) to moderate (in the most caudal sections of the rostral DR; Fig. 7A-C, Table 1 ) number of CRF 2 receptor-ir cells. Although some CRF 2 receptor-ir cells were apparent in structures adjacent to the DR, such as the periaqueductal gray region (Fig. 7D) both the density and intensity of staining of cells were lower compared to regions in the DR.
In the rostral DRD, CRF 2 receptor-ir cells were dense near the cerebral aqueduct (Aq) at the midline, although some were located outside the boundaries of the DRD laterally (Fig. 7A, B) . In the most rostral part of the rostral DR, the majority of CRF 2 receptor-ir cells were located along the midline within the DR (with some cells scattered outside the DR, in the adjacent oculomotor complex and periaqueductal gray; Fig. 7A, B) . Large, densely stained CRF 2 receptor-ir cells were observed within the paratrochlear nucleus (Pa4; Fig. 7A, C) .
CRF 2 receptor immunostaining in the mid-rostrocaudal DR
Mid-rostrocaudal regions of the DR (Ϫ7.73 mm to Ϫ8.45 mm bregma) contained the greatest density and numbers of CRF 2 receptor-ir cells in the DR (Fig. 8, Table 1 ). The largest numbers of CRF 2 receptor-ir cells were located in the DRV, particularly at and around Ϫ8.00 mm bregma (104.2Ϯ3.9 cells). At this level, although there were also many CRF 2 receptor-ir cells scattered around the midline of the DRV, there were bilateral clusters of intensely stained CRF 2 receptor-ir cells above the medial longitudinal fasciculus (mlf) on either side of the midline (Fig. 8A,  C) . The majority of CRF 2 receptor-ir cells were dorsal to the mlf, but some were located between the fiber bundles of the mlf with a few cells in the region lateral to the superior cerebellar peduncle (Fig. 8A, C) . A dense central cluster of CRF 2 receptor-ir cells in the midline was located in the DRD throughout the mid-rostrocaudal DR (Fig. 8A,  B) , a region referred to as the DRD core region by Abrams et al. (2005) . There also were some CRF 2 receptor-ir cells scattered outside this dense cluster (Fig. 8A, B) , within a region referred to as the DRD shell region by Abrams et al. (2005) . Scattered CRF 2 receptor-ir cells were present in the DRVL region (Fig. 8A, D) .
CRF 2 receptor immunostaining in the caudal DR
Caudal regions of the DR (Ϫ8.54 mm to Ϫ9.26 mm bregma) contained fewer numbers of CRF 2 receptor-ir cells (Fig. 9A-C, Table 1 ), relative to the mid-rostrocaudal DR. CRF 2 receptor-ir cells within the caudal DR were observed in the DRI where a small number of cells, oriented in a vertical plane between the mlf, were arranged in bilateral columns (Fig. 9A, C ). There were, however, a few scattered, intensely stained CRF 2 receptor-ir cells dorsal to the DRI, in the DRC (Fig. 9A, B ). These were located in the midline ventrally, extending laterally in clusters of cells located just below the cerebral aqueduct in the dorsal part of the DRC (Fig. 9A, B) . Lateral to the DRC, scattered CRF 2 receptor-ir cells were observed within the lateral and pericentral part of the dorsal tegmental nucleus (LDTg, DTgP; Fig. 9A, D) .
CRF 2 receptor/TrpOH double immunofluorescence
CRF 2 receptor and TrpOH immunofluorescence were found throughout the rostrocaudal extent of the DR (Figs. 10 and 11). CRF 2 receptor immunofluorescence was found outside of the DR, but it was most prominent in the Fig. 10D-F) . In addition, a significant proportion of TrpOH-positive neurons also expressed CRF 2 receptors, (32.5-58.1%, depending on the subdivision) (Fig. 10G-I ,  Table 1 ), which is consistent with previous studies describing co-localization of CRF 2 receptor and serotonin transporter mRNA expression (Day et al., 2004) .
DR (
DISCUSSION
CRF 2 receptor-ir cells were distributed throughout the rostrocaudal extent of the DR, with clear regional differences in the number and density of cells. There were low to moderate numbers of CRF 2 receptor-ir cells within the rostral and caudal DR. The highest densities and the greatest numbers of CRF 2 receptor-ir cells were observed in the mid-rostrocaudal DR. At this anatomical level, CRF 2 receptor-ir cells were observed in the dorsal, ventral, and, to a lesser extent, the ventrolateral parts of the DR. The highest densities of CRF 2 receptor-ir cells within the DRD, DRV, and DRI corresponded to the location of the highest densities of serotonergic neurons in these regions (Steinbusch, 1981 ). In agreement with previous studies of CRF 2 and serotonin transporter mRNA expression (Day et al., 2004) , CRF 2 receptor immunofluorescence was co-localized with TrpOH-ir neurons. These data show that CRF 2 receptor-ir cells are expressed throughout the DR, but the highest concentrations seem to be restricted to specific subdivisions of the mid-rostrocaudal DR and in some cases specific parts of these subdivisions. These data indicate that CRF 2 receptor mRNA expression previously described in the DR is associated with CRF 2 receptor immunostaining of perikarya, and that the topographical distributions of the CRF 2 receptor mRNA and protein expression are similar, including expression in serotonergic neurons.
Technical considerations
Immunostaining resulted in clear CRF 2 receptor immunostaining of perikarya within the DR and other brain regions with high levels of CRF 2 receptor mRNA expression. Recent studies by Waselus et al. (2009) using electron microscopy and immunogold labeling have demonstrated that CRF 2 receptor immunoreactivity is predominantly cytoplasmic in DR neurons under basal unstressed conditions (with a ratio of cytoplasmic to total immunogold particles of 0.85Ϯ0.01), and shifts toward a greater expression at the plasma membrane following stress exposure (with a ratio of cytoplasmic to total immunogold particles of 0.56Ϯ0.03). Although we cannot distinguish plasma membrane-associated from cytoplasmic CRF 2 receptor in our studies, our data are suggestive of expression of CRF 2 receptor in both cellular compartments in unstressed rats, consistent with findings by Waselus et al. (2009) . Interestingly, the anti-CRF 2 receptor antibodies used in the studies by Waselus et al. (2009) and in our studies were both directed at the N-terminus of the CRF 2 receptor (human CRF 2 receptor; Novus Biologicals, personal communication), and both identified a single major band between 37 and 50 kDa, as determined using western blot (Wang et al., 2007) .
CRF 2 receptor isoforms
It is possible that the CRF 2 receptor immunostaining described here represents immunostaining of CRF 2␣ , CRF 2␤ , CRF 2␣-tr , and/or soluble (s)CRF 2␣ receptor isoforms in the rat DR. The antibody that was used is likely to recognize all known isoforms of the CRF 2 receptor because the antibody recognizes a 12-amino acid sequence of the N-terminus that is nearly identical in all CRF 2 receptor isoforms that have been characterized (Fig. 1) . A recent study (Evans and Seasholtz, 2009 ) has shown that the sCRF 2␣ receptor is found in the rat brain, and that the mRNA is efficiently translated. In addition Evans and Seasholtz (2009) showed that the sCRF 2␣ receptor is not trafficked to the membrane, which may account in part for the apparent abundance of cytoplasmic staining seen in this study and previous studies (Waselus et al., 2009) . Consistent with these findings, recent studies by Schulz and colleagues (2010) showed that CRF 2␣ receptor contains an N-terminal pseudo signal peptide that is unable to target the peptide to the endoplasmic reticulum membrane, resulting in very low cell surface expression (Schulz et al., 2010) . Furthermore, Tian and colleagues (Tian et al., 2006) showed that the sc-1826 antibody recognizes the CRF 2␣-tr receptor isoform using western blot analysis (band at 16 -32 kDa) in the forebrain, olfactory bulb, and cerebellum of rats and mice. The sc-1826 antibody was also shown to recognize the CRF 2␣-tr receptor in HEK-293 cells expressing the CRF 2␣-tr receptor isoform, using both immunocytochemistry and western blot analysis (Tian et al., 2006) . Based on the immunohistochemical and immunofluorescence results in our study, together with in situ hybridization studies, recep- Fig. 6 . Western blot analysis using the anti-CRF 2 receptor antibody (sc-1826) in microdissected rat brain tissue. In all brain regions analyzed, the anti-CRF 2 receptor antibody recognized one major band at between 37 and 50 kDA, which corresponds to the predicted molecular weight of the full-length CRF 2 receptor. The density of the bands in different brain regions corresponded with the density of CRF 2 receptor mRNA expression previously described in rat brain. Band density was highest in the lateral septum (LS), whereas it was lower in cortical regions such as the entorhinal cortex (En) and motor cortex (M1). There were no differences in actin levels among the different regions. Results are representative of three replicate western blots. Abbreviations: DR, dorsal raphe nucleus; En, entorhinal cortex; LS, ventral part of the lateral septum; M1, motor cortex; MnR, median raphe nucleus; MWM, molecular weight markers; VMH, ventromedial hypothalamus. tor autoradiography studies, and functional studies using direct microinjections of selective CRF 2 receptor agonists and antagonists within the DR, it seems likely that at least one high-affinity receptor for CRF 2 receptor ligands is present in the DR, and perhaps more. Future work using specific antibodies or probes will be required to determine which isoform(s) of the CRF 2 receptor are expressed in the DR, their relative abundance, and functional properties.
Topography of the distribution of CRF 2 receptor-ir cells in the DR
The dorsal and ventral portions of the mid-rostrocaudal DR, where we observed the greatest concentrations of CRF 2 receptor-ir cells, have unique patterns of anatomical projections to and from forebrain limbic structures. The mid-rostrocaudal DRD (relative to other subdivisions of the DR) is known to receive strong projections from specific forebrain structures including the prelimbic cortex, central amygdaloid nucleus, bed nucleus of the stria terminalis, medial and lateral preoptic area, paraventricular nucleus of the hypothalamus, and dorsal hypothalamic area (Peyron et al., 1998; Vertes, 2004) . The mid-rostrocaudal DRD is known to project to a number of forebrain regions involved in regulation of emotional behavior, including the medial prefrontal cortex, basolateral amygdaloid nucleus, central amygdaloid nucleus, nucleus accumbens, dorsal hypothalamic nucleus, and bed nucleus of the stria terminalis (Imai et al., 1986; Van Bockstaele et al., 1993; Petrov et al., 1994; Petit et al., 1995; Commons et al., 2003; Abrams et al., 2005) . This pattern of projections suggests that this region provides a major contribution to the dorsal raphe forebrain tract, one of six major serotonergic tracts innervating the forebrain (Azmitia and Segal, 1978; Azmitia, 1981; Lowry et al., 2008) . The mid-rostrocaudal DRV also contains large numbers of neurons projecting to the basolateral amygdaloid nucleus (Abrams et al., 2005) as well as large numbers of neurons projecting to the caudate putamen and horizontal limb of the diagonal band of Broca (Steinbusch et al., 1980; Steinbusch, 1981; Semba et al., 1988) . The mid-rostrocaudal DRV (relative to other subdivisions of the DR) receives strong projections from the lateral orbital cortex and medial and lateral preoptic areas (Peyron et al., 1998) . Some of the forebrain regions that project to the mid-rostrocaudal DR contain neurons that express Ucn 2 and Ucn 3, both of which have high affinity for CRF 2 receptors and therefore could be sources of endogenous ligand(s) acting on full-length CRF 2 receptors within the DR (reviewed by Reul and Holsboer, 2002) . For example, neurons within the paraventricular nucleus of the hypothalamus express Ucn 2 mRNA while neurons within the bed nucleus of the stria terminalis and medial and lateral preoptic areas express Ucn 3 mRNA (Peyron et al., 1998; Lewis et al., 2001; Reyes et al., 2001; Li et al., 2002) . Consistent with the hypothesis that urocortins play an important role in regulation of serotonergic systems and behavior, Ucn 1/Ucn 2 knockout mice (Neufeld-Cohen et al., 2010a) as well as Ucn 1/Ucn 2/Ucn 3 triple knockout mice have altered baseline serotonergic activity in neural systems regulating anxiety states and altered anxiety-like behavior (Neufeld-Cohen et al., 2010b) . It is known that Ucn 1-ir neurons from the Edinger-Westphal nucleus also project to the DR (Bittencourt et al., 1999) , but it is currently unclear if the DR is also innervated by Ucn 2-, or Ucn 3-containing fibers. As the DR is one of the few brain structures where CRF 2 receptor mRNA expression is higher than CRF 1 receptor mRNA expression, future studies should examine the innervation of the DR by highaffinity CRF 2 receptor ligands including Ucn 2 and Ucn 3 and the sources of fibers containing these CRF-related neuropeptides.
Electrophysiological responses to CRF 2 receptor ligands in the DR
The current study, describing high numbers of CRF 2 receptor-ir cells in the mid-rostrocaudal DR, is in agreement with a number of electrophysiological studies investigating the effects of CRF and CRF-related neuropeptides on serotonergic neuronal firing rates. Electrophysiological studies provide strong evidence that functional CRF 2 receptors are expressed within the mid-rostrocaudal DR. Low concentrations of ovine CRF, concentrations that are likely to bind to CRF 1 receptors (Primus et al., 1997) , microinjected into the DR decrease the in vivo neuronal firing rates of DR serotonergic neurons (Kirby et al., 2000) , while high concentrations of ovine CRF, doses that are likely to bind to CRF 1 and CRF 2 receptors (Primus et al., 1997) , increase both in vivo and in vitro firing rates of DR serotonergic neurons (Lowry et al., 2000; Kirby et al., 2000) . In vitro extracellular recording studies by Lowry and colleagues (Lowry et al., 2000) revealed that the majority of presumed serotonergic neurons activated by CRF were located in the mid-rostrocaudal DRV relative to the midrostrocaudal DRD. These in vitro extracellular recordings are consistent with our current findings, as the highest density of CRF 2 receptor-ir cells were found in the midrostrocaudal DRV region. Microinjections of low doses of Ucn 2 (mUcn 2; Valentino, personal communication) into the mid-rostrocaudal DR of anesthetized rats inhibits the firing rates of serotonergic neurons, while injections of high doses of mUcn 2 into the same region increase the firing rates of serotonergic neurons (Pernar et al., 2004) . Thus, the concentrations of both CRF and mUcn 2 appear to be critical for their effects on the neuronal activity of serotonergic neurons in the DR, with a possibility of both inhibitory and excitatory responses depending on the local concentration of ligand. Future studies should take into account the rostrocaudal and dorsoventral differences in the distribution of CRF 2 receptors as well as the possibility of the presence of multiple isoforms of CRF 2 receptors in the DR.
Functional implications-anxiety-related physiological and behavioral effects of CRF 2 receptor ligands in the DR
Our current findings of high numbers of CRF 2 receptor-ir cells in the mid-rostrocaudal DR are in agreement with a number of studies investigating neurochemical and behavioral responses to intra-DR injections of CRF 2 receptor ligands. Direct microinjections of mUcn 2 into the DR induce potentiation of fear conditioning and escape deficits measured 24 h later in a model of learned helplessness (Hammack et al., 2003a) . This potentiation of fear conditioning and escape deficits is prevented by prior injections of ASV-30 but not the CRF 1 receptor antagonist 2-methyl-4-(N-propyl-N-cycloproanemethylamino)-5-chloro-6-(2,4,6-trichloranilino)pyrimidine (NBI27914) (Hammack et al., 2003b) . Furthermore, the potentiation of fear conditioning and escape deficits was observed following injections of high doses of CRF (doses likely to bind to CRF 2 receptors (Primus et al., 1997) ) into the caudal, but not the rostral, DR (Hammack et al., 2002) . These functional studies suggest that activation of CRF 2 receptors within the DR, particularly within the mid-rostrocaudal and caudal DR may play an important role in the regulation of emotional behavior. Intra-DR microinjections of Ucn 1, which binds with high affinity to both CRF 1 and CRF 2 receptors, have also been shown to induce physiological and behavioral responses. Intra-DR injections of Ucn 1 induce hypothermia and decrease food and fluid consumption in mice (Turek and Ryabinin, 2005; Weitemier and Ryabinin, 2006) . Furthermore, intra-DR injections of the CRF 2 receptor antagonist ASV-30 prevent ethanol-induced hyperthermia (Turek and Ryabinin, 2005) . Together, these functional studies support the hypothesis that CRF 2 receptors within the DR are involved in the regulation of multiple physiological and behavioral responses, consistent with their widespread distribution in the DR.
CONCLUSION
In conclusion, this study describes for the first time the distribution of CRF 2 receptor-ir cells throughout the DR. The highest numbers and the highest densities of CRF 2 receptor-ir cells were found in the mid-rostrocaudal DR, particularly in the DRD and DRV subdivisions. Together with previous studies, these findings are consistent with the hypothesis that CRF 2 receptor activation within the mid-rostrocaudal and caudal DR is an important component of neural mechanisms regulating anxiety-or stressrelated physiological and behavioral responses. Based on the widespread distribution of CRF 2 receptors in the DR and the functional heterogeneity of the DR, CRF 2 receptors in this region are likely to modulate diverse physiological and behavioral responses.
Functionally integrated CRF and mesolimbocortical serotonergic systems arising from the mid-rostrocaudal and caudal DR are likely to play an important role in stressrelated psychopathology including anxiety and mood disorders, as well as stress-induced relapse to drug abuse (Arborelius et al., 1999; Sarnyai et al., 2001; Heinrichs and Koob, 2004) . CRF innervation of the human DR is greatest in the mid-to caudal levels (Austin et al., 1997) , and depressed patients have increased CRF immunoreactivity in the caudal subnucleus of the DR (Austin et al., 2003) . In addition, recent studies of human depressed suicide patients have revealed that the widely reported increases in tryptophan hydroxylase 2 (tph2) mRNA and protein expression in the DR (Underwood et al., 1999; Bonkale et al., 2006; Bach-Mizrachi et al., 2006) may be restricted to the caudal subnucleus (Bach-Mizrachi et al., 2008) and its projection sites (Perroud et al., 2010) . Consequently, dysregulation of CRF 2 receptor signaling within the caudal DR may have important implications for affective disorder and other stress-related neuropsychiatric disorders. Fig. 11 . Photomicrographs of CRF 2 receptor immunofluorescence and tryptophan hydroxylase (TrpOH) immunofluorescence in the rat DR that was used for quantification. Photomicrographs of TrpOH immunofluorescence (panels A-F), CRF 2 receptor immunofluorescence (panels BԺ, DԺ, FԺ), DAPI (BԺԺ, DԺԺ, FԺԺ), and CRF 2 receptor/TrpOH/DAPI triple immunofluorescence (BԺԺԺ, DԺԺԺ, FԺԺԺ) at a rostral anatomical level (Ϫ7.64). Row (A-BԺԺԺ) represents the dorsal raphe nucleus, dorsal part (DRD), row (C-DԺԺԺ) represents the dorsal raphe nucleus, ventral part (DRV) and row (E-FԺԺԺ) represents the dorsal raphe nucleus, ventrolateral part (DRVL). Scale bar for panels: (A, C, E), 50 m; scale bar for rest of panels: 100 m). For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.
